CDMO

First GMP batch of plant-derived cholesterol produced at the new Tippecanoe facility; full capacity planned by mid-2027 to support LNP-based therapies.

Signed a Sept 25, 2026 agreement to join a global CDMO alliance for cell and gene therapy, aiming to expand manufacturing support, quality tools and cross-region collaboration.

Process development and GMP manufacturing of lactoperoxidase and glucose oxidase to support an IND filing and a Phase II clinical trial in the US.

Showcased quality, global dual‑sourcing and European capacity (Dundalk 54,000 L, Wuppertal 12–24,000 L) alongside platform speeds for complex biologics and 1,064 active projects.

Yokohama technical center began cell therapy process development in July 2025 and has been awarded multiple exosome and T‑cell projects, including a program transferred from Milan.

Feasibility study to combine Fol‑Dab8 (folate‑conjugated cationic peptide) with naturally occurring microRNA for oligonucleotide therapeutics; undisclosed equity investment made.

€15m first tranche of a €35m package to expand a Colombian plant to produce up to 250m doses annually, plus a €1.5m R&D grant for three vaccine candidates.

Passed a two-week unannounced FDA GMP inspection covering drug substance and drug product manufacturing, reinforcing U.S. commercial supply reliability.

Shows preservative solutions for pet care, launches biodegradable Cosmelin esters as a silicone alternative, presents Scopeblue lower‑carbon preservatives and an Oct 16 LCA talk.

Aligns businesses by role, assigns roles to six German sites, and shifts investment to Asia/Americas; launches growth projects in Canada and Slovakia, funded by cost cuts.